Common Equity: The sum of all common equity items.
MoonLake Immunotherapeutics (MLTX) had Common Equity of $357.94M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-55.22M |
|
-- |
|
-- |
|
$60.70M |
|
$-60.70M |
|
$4.74M |
|
$-55.96M |
|
$-55.96M |
|
$-56.05M |
|
$-56.05M |
|
$-56.05M |
|
$-56.05M |
|
$-60.70M |
|
$-59.96M |
|
63.28M |
|
63.28M |
|
$-0.87 |
|
$-0.87 |
|
| Balance Sheet Financials | |
$455.48M |
|
$0.67M |
|
$4.62M |
|
$460.10M |
|
$27.36M |
|
$73.38M |
|
$74.79M |
|
$102.15M |
|
|
Common Equity |
$357.94M |
$357.94M |
|
$357.94M |
|
64.20M |
|
| Cash Flow Statement Financials | |
$-92.67M |
|
$144.50M |
|
$73.12M |
|
$180.43M |
|
$306.68M |
|
$126.25M |
|
$5.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.65 |
|
-- |
|
-- |
|
0.17 |
|
0.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-92.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.66% |
|
-15.66% |
|
-12.18% |
|
-13.00% |
|
$5.58 |
|
$-1.46 |
|
$-1.46 |
|